910 related articles for article (PubMed ID: 7635795)
1. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
3. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
[TBL] [Abstract][Full Text] [Related]
4. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
[TBL] [Abstract][Full Text] [Related]
5. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
6. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
7. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study.
Bradley JD; Dehdashti F; Mintun MA; Govindan R; Trinkaus K; Siegel BA
J Clin Oncol; 2004 Aug; 22(16):3248-54. PubMed ID: 15310768
[TBL] [Abstract][Full Text] [Related]
11. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
12. F18-FDG-PET/CT in the evaluation of patients with suspected recurrent or persistent locally advanced cervical carcinoma.
Cetina L; Serrano A; Cantú-de-León D; Pérez-Montiel D; Estrada E; Coronel J; Hernández-Lucio M; Dueñas-González A
Rev Invest Clin; 2011; 63(3):227-35. PubMed ID: 21888286
[TBL] [Abstract][Full Text] [Related]
13. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
14. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer.
Ebright MI; Russo GA; Gupta A; Subramaniam RM; Fernando HC; Kachnic LA
J Thorac Cardiovasc Surg; 2013 Mar; 145(3):709-15. PubMed ID: 23317944
[TBL] [Abstract][Full Text] [Related]
17. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
[TBL] [Abstract][Full Text] [Related]
18. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
[TBL] [Abstract][Full Text] [Related]
19. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
20. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]